Bellicum Pharmaceuticals (NASDAQ:BLCM) Share Price Crosses Above 50-Day Moving Average of $0.08

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.08 and traded as high as $0.09. Bellicum Pharmaceuticals shares last traded at $0.07, with a volume of 6,000 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Bellicum Pharmaceuticals in a report on Tuesday. They issued a “sell” rating for the company.

Bellicum Pharmaceuticals Stock Down 6.6 %

The business has a fifty day moving average of $0.08 and a 200-day moving average of $0.14.

Institutional Trading of Bellicum Pharmaceuticals

An institutional investor recently bought a new position in Bellicum Pharmaceuticals stock. HRT Financial LP bought a new position in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned 0.42% of Bellicum Pharmaceuticals as of its most recent SEC filing. 4.93% of the stock is currently owned by institutional investors and hedge funds.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.